hta in developing countries

hta in developing countries

DCIG invites you to submit a 1000- to 4000- word piece on a topic pertinent to low- and middle-income countries for a competition. The written pieces will be published on the IG website under the title “Emerging Issues Relevant to Developing Countries.” 

The winners of the competition will be awarded a monetary prize. There are four categories:

  1. A 700 CAD first-place prize (a paper with 4000 words)
  2. A 600 CAD second-place prize (a paper with 3000 words)
  3. Two third-place prizes of 500 CAD each (paper with 2000 words); and,
  4. Four additional prizes of 200 CAD each (paper with 1000 words).

———————————————————————————-

Please note the following: 

  1. The topics must pertain to Covid-19/public health emergencies or health technologies or technologies for unmet needs or other topics of relevance to the needs of developing countries.
  2. The winning paper may be published in IJTAHC after undergoing the required peer review process.
  3. The author(s) of the winning essays must present their topic at a webinar within two months of receiving their award. This webinar will be open for all members to attend.
    1. The winners of the additional prizes of 200 CAD may present their topics at the same webinar as a single group. 
    2. The award money will be sent to the winners after the webinar’s conclusion. 
  4. Only one submission is permitted per member or group of members. 
  5. Submissions will be accepted until 30 April 2023, followed by a three-month review period. You will receive notifications in August 2023. 
  6. If you would like your paper to be considered for the contest, please submit it to  [email protected]
  7. In addition, the articles must adhere to the following criteria: 
    1. The concept is appropriate to HTA/HTAi
      1. It should align with the proposed topics
      2. The overall strategy, methodology, and analyses are well-reasoned and appropriate for achieving the specified objective of the paper
    2. The content leads to original and innovative contributions. A paper with original and innovative ideas based on one of the proposed themes will receive a higher score. 
      1. It addresses an innovative hypothesis or major barrier/issue to progress in the field
      2. It is based on novel concepts, approaches or methodologies, tools, or technologies
      3. It challenges current practices or existing paradigms.
    3. The paper meets the following quality and structural requirements
      1. Introduction:
        1. It provides scientific background, an explanation of the rationale, and a clear statement of the problem, topic, study purpose, objectives, and/or research hypothesis.
        2. It must be clearly stated to receive the highest score.
      2. Methods
        1. For quantitative and related studies, a clear perspective statement, data collection, data sources, and analyses, including statistical testing, policy analysis of alternatives, issues examined, and the like, were conducted.
        2. A clear description of the studied population, a method to accrue populations, a sample frame, and analytic techniques are required.
      3. Results
        1. The result section presents the important study findings (qualitative or quantitative), including (if relevant) generalizability to other populations, health systems, or countries.
      4. Conclusions
        1. It should provide a concise statement on important findings and policy implications. It should address the next steps and/or the optimal course of action, and study limitations

Please email us at [email protected] if you have any questions. Best of luck with your writing, and we wish you all the best.

HTAi 2020 Annual Meeting

2020 HTAi HTA IN DEVELOPING COUNTRIES INTEREST GROUP ANNUAL BUSINESS MEETING

This Annual Business Meeting is a requirement and part of the activities mandated by the Developing Interest Group.

The meeting shall be an interactive session that will bring together as many members of the interest group in good standing to discuss several topics concerning the group.

The agenda includes, but is not limited to the following

1. Welcome

2. Approval of minutes from Business Meeting 2019

3. Report back from HTAi IG Steering Committee meetings

4. IG activities in preparation for next Annual Meeting 2021 to be held in Manchester

5. Other Business

Regional Projects

DCIG newsletter

In lieu of a physical meeting this year due to the global COVID-19 pandemic, this meeting shall be held virtually.

DATE:

August 11, 2020

TIME:

08:00 – 09:00 MDT (UTC -6)

VIEW THE RECORDING

Upcoming Webinars

HTA Informing Innovative Drugs’ Market Access in Low- and Middle-Income Countries

Join us for a live webinar presented by HTA in Developing Countries Interest Group (DCIG) “HTA Informing Innovative Drugs’ Market Access in Low- and Middle-Income Countries” on December 2, 3:00 a.m. MST (10:00 a.m. UTC).

The WHO identifies achieving Universal Health Coverage (UHC) as a strategic priority, encompassing a full range of essential health services, of which technology constitutes a core component. It is a significant challenge for many countries, especially low- and middle-income countries (LMICs), to increase their use of scarce public resources to ensure their citizens’ access to innovative pharmaceuticals. The dilemma of high costs, limited access, and UHC calls for innovative approaches and solutions.

This webinar demonstrates how HTA informs innovative drugs market access in different LMICs, and it could address how HTA researchers or HTA institutions respond to the innovative technology with capacity competency. It is a pilot to facilitate HTA communication and collaboration by DCIG. It will map market entry, reimbursement policy for innovative drugs and HTA roles, value frameworks and methodology, institutional challenges, and potential regional/international HTA collaboration.

Speakers will present innovative drugs market entry and reimbursement in different continents, analyzing how HTA is conducted and the value frameworks used in different countries. It will summarize challenges to HTA capacity or competency and information shared with other countries for reference

  • Moderator: Yingyao Chen
  • Jeonghoon, from Korea, Korea experience
  • Debora Aligieri (Patient representative Brazil)
  • Salome Meyer (Patient representative, Cancer Association, South Africa)
  • Kiusiang Tay-Teo, (Health Products Policy and Standards Medicines and Health Products, WHO.
  • Mouna Jameleddine, INEAS, Tunisia

Join us live on Youtube

HTAi 2020 Annual Meeting

2020 HTAi HTA IN DEVELOPING COUNTRIES INTEREST GROUP ANNUAL BUSINESS MEETING

This Annual Business Meeting is a requirement and part of the activities mandated by the Developing Interest Group.

The meeting shall be an interactive session that will bring together as many members of the interest group in good standing to discuss several topics concerning the group.

The agenda includes, but is not limited to the following

1. Welcome

2. Approval of minutes from Business Meeting 2019

3. Report back from HTAi IG Steering Committee meetings

4. IG activities in preparation for next Annual Meeting 2021 to be held in Manchester

5. Other Business

Regional Projects

DCIG newsletter

In lieu of a physical meeting this year due to the global COVID-19 pandemic, this meeting shall be held virtually.

DATE:

August 11, 2020

TIME:

08:00 – 09:00 MDT (UTC -6)

VIEW THE RECORDING

Upcoming Webinars

HTA Informing Innovative Drugs’ Market Access in Low- and Middle-Income Countries

Join us for a live webinar presented by HTA in Developing Countries Interest Group (DCIG) “HTA Informing Innovative Drugs’ Market Access in Low- and Middle-Income Countries” on December 2, 3:00 a.m. MST (10:00 a.m. UTC).

The WHO identifies achieving Universal Health Coverage (UHC) as a strategic priority, encompassing a full range of essential health services, of which technology constitutes a core component. It is a significant challenge for many countries, especially low- and middle-income countries (LMICs), to increase their use of scarce public resources to ensure their citizens’ access to innovative pharmaceuticals. The dilemma of high costs, limited access, and UHC calls for innovative approaches and solutions.

This webinar demonstrates how HTA informs innovative drugs market access in different LMICs, and it could address how HTA researchers or HTA institutions respond to the innovative technology with capacity competency. It is a pilot to facilitate HTA communication and collaboration by DCIG. It will map market entry, reimbursement policy for innovative drugs and HTA roles, value frameworks and methodology, institutional challenges, and potential regional/international HTA collaboration.

Speakers will present innovative drugs market entry and reimbursement in different continents, analyzing how HTA is conducted and the value frameworks used in different countries. It will summarize challenges to HTA capacity or competency and information shared with other countries for reference

  • Moderator: Yingyao Chen
  • Jeonghoon, from Korea, Korea experience
  • Debora Aligieri (Patient representative Brazil)
  • Salome Meyer (Patient representative, Cancer Association, South Africa)
  • Kiusiang Tay-Teo, (Health Products Policy and Standards Medicines and Health Products, WHO.
  • Mouna Jameleddine, INEAS, Tunisia

Join us live on Youtube

DCIG Organizational Information

Chair: Debjani Mueller, South Africa
Technical Officer: Yves Miel Zuniga, Phillipines

HTAi Bylaws

DCIG Terms of Reference